The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 131I whole body scan: A single-center study of 108 patients

Annals of Nuclear Medicine

Volumn 20, Issue 8, 2006, Pages 547-552

  Choi, Mi Yeon ^a   Chung, June Key ^a   Lee, Ho Yeong ^a   So, Young ^a   Park, Do Joon ^a   Jeong, Jae Min ^a   Lee, Dong Soo ^a   Lee, Myung Chul ^a   Cho, Bo Youn ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

131I whole body scan; 18F fluorodeoxyglucose ( 18F FDG); Papillary thyroid cancer; Positron emission tomography (PET); Thyroglobulin (Tg)

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN ANTIBODY; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CERVICAL LYMPH NODE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; TUMOR LOCALIZATION; TUMOR RECURRENCE; WHOLE BODY SCINTISCANNING; CARCINOMA; CHEMISTRY; METHODOLOGY; MIDDLE AGED; PAPILLARY CARCINOMA; SCINTISCANNING; THYROID TUMOR; WHOLE BODY IMAGING;

ADULT; AGED; CARCINOMA; CARCINOMA, PAPILLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; THYROGLOBULIN; THYROID NEOPLASMS; WHOLE BODY IMAGING;

EID: 33751422376     PISSN: 09147187     EISSN: 09147187     Source Type: Journal    
DOI: 10.1007/BF03026819     Document Type: Article

References (27)

1. Pacini F, DeGroot LJ. Thyroid neoplasia. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 4th ed. Philadelphia; Saunders, 2001: 1541-1566.
2. Spencer CA. Thyroglobulin. In: Braverman LE, Utiger RD, editors. Werner and Ingbar's The Thyroid: The Fundamental and Clinical Text. 7th ed. Philadelphia; Lippincott-Raven, 1996: 406-415.
3. Filesi M, Signore A, Ventroni G, Melacrinis F, Ronga G. Role of initial iodine-131 whole body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med 1998; 39: 1542-1546.
4. Roelants V, Nayer P, Bouckaet A, Beckers C. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24: 722-727.
5. Ronga G, Fiorentino A, Paserio E, Signore A, Todino V, Tummarello MA, et al. Can iodine-131 whole body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med 1990; 31: 1766-1771.
6. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Eng J Med 1998; 338: 297-306.
7. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80: 1488-1492.
8. 131I-negative papillary thyroid carcinoma. J Nucl Med 2000; 41: 1010-1015.
9. Unal S, Menda Y, Adalet I, Boztepe H, Ozbey N, Alagol F, et al. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases. J Nucl Med 1998; 39: 1897-1902.
10. Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1998; 39: 870-875.
11. 99mTc-sestamibi scintigraphy in differentiated thyroid carcinoma. Thyroid 1997; 7: 327-335.
12. 131I in patients with metastatic thyroid carcinoma. Nucl Med Commum 1997; 18: 3-9.
13. 131I whole-body scan. J Nucl Med 1999; 40: 986-992.
14. 131I scan. J Nucl Med 2001; 42: 71-76.
15. 18F-2-fluoro-2-deoxy-D-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? Eur J Endocrinol 2003; 149: 293-300.
16. 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84: 2291-2302.
17. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987; 28: 910-914.
18. Larson SM, Robins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002; 37: 169-174.
19. Feine U, Leitzenmayer R, Hanke JP, Held J, Worhle H, Muller-Schenbrg W. Fluorine-18-FDG and Iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1997; 37: 1468-1472.
20. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26: 1547-1552.
21. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24: 1342-1348.
22. Kim S, Chung J-K, Shin JH, Min HS, Kang JH, So Y, et al. Expression patterns on N-ras oncogene, glucose transporter-1 gene and thyroid specific genes in papillary thyroid carcinoma. J Nucl Med 2003; 44: 41p.
23. Westbury C, Vini L, Fisher C, Harmer C. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid 2000; 10: 171-176.
24. Chung JK, Lee YJ, Jeong JM, Lee DS, Lee MC, Cho BY, et al. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med 1997; 38: 1191-1195.
25. Schober B, Cohen P, Lyster D, Charron M, Lentle B. Diffuse liver uptake of iodine-131 [Letter]. J Nucl Med 1990; 31: 1575-1576.
26. Maayan ML, Eisenberg J, Lopez EM, Rothschild MA. Hepatic visualization after iodine-131 in patients with thyroid carcinoma. N Engl J Med 1986; 295: 1258-1270.
27. Albert DM, Puliafito CA. Hepatic visualization after iodine-131 in patients with thyroid carcinoma [Letter]. N Engl J Med 1977; 296: 634.